Watchlist Price Alert

Evotec SE (EVO)

NASDAQ: EVO · Real-Time Price · USD

4.15

0.10 (2.47%)

At close: May 07, 2025, 3:59 PM

4.24

2.17%

After-hours: May 07, 2025, 06:55 PM EDT

2.47% (1D)

Bid	3.46
Market Cap	2.95B
Revenue (ttm)	796.97M
Net Income (ttm)	-196.08M
EPS (ttm)	-0.66
PE Ratio (ttm)	-6.29
Forward PE	-331
Analyst	Hold

Ask	4.44
Volume	406,922
Avg. Volume (20D)	94,870
Open	4.13
Previous Close	4.05
Day's Range	4.00 - 4.18
52-Week Range	2.84 - 5.68
Beta	1.11

About EVO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EVO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Evotec SE has released their quartely earnings on May 6, 2025:

Revenue of $210.3M misses estimates by $5.16M, with -7.23% YoY decline.

EPS of -0.095 exceeds estimates by 0.14, with -46.15% YoY decline.

Next Earnings Release

Evotec SE is scheduled to release its earnings on Aug 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+10.09%

Evotec shares are trading higher. The company repo... Unlock content with Pro Subscription

5 months ago

-16.07%

Evotec shares are trading lower after Halozyme withdrew its €2 billion proposal to acquire the company.

News

1 day ago · accessnewswire.com

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partn...

2 days ago · seekingalpha.com

Evotec SE (EVO) Q1 2025 Earnings Call Transcript

Evotec SE (NASDAQ:EVO ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Volker Braun - Head, Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin...

2 days ago · accessnewswire.com

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation pa...

1 week ago · accessnewswire.com

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 20...

2 weeks ago · accessnewswire.com

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE /...

2 weeks ago · seekingalpha.com

Evotec SE (EVO) Q4 2024 Earnings Call Transcript

Evotec SE (NASDAQ:EVO ) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hi...

3 weeks ago · accessnewswire.com

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value ...

3 weeks ago · accessnewswire.com

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 Ap...

2 months ago · accessnewswire.com

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / E...

2 months ago · accessnewswire.com

Evotec Announces Change in Management Board

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire ...

Load More News